New Educational Resource Helps Canadian Patients Find Information to Access Investigational Medicines
July 4, 2015
Caligor Rx, a global leader in Global Access Programs and pharmaceutical sourcing and supply for clinical trials, today announced that it has partnered with Global Genes™, a leading rare disease patient advocacy organization, to create a patient-focused RARE Toolkit entitled, “Access to Unapproved Medicine: Is this an option for me? (Canada)” (see link: https://globalgenes.org/toolkits/accesscanada/intro/).
“Caligor Rx is proud to partner with Global Genes in an effort to inform and empower patients and patient advocates on their options for obtaining much needed medicines in Canada, particularly in the area of rare diseases, where there is high unmet medical need”
“Caligor Rx’s extensive knowledge of the regulatory requirements necessary to access unlicensed medicines, and its global expertise in securing these important medicines for patients, make the Company an invaluable partner for this initiative,” said Global Genes President and Founder Nicole Boice. “Caligor Rx’s contribution to this resource will help inform the rare disease community in Canada, creating a new educational pathway to potential treatment options.”
“Caligor Rx is proud to partner with Global Genes in an effort to inform and empower patients and patient advocates on their options for obtaining much needed medicines in Canada, particularly in the area of rare diseases, where there is high unmet medical need,” said Karen Frascello, the Company’s Vice President of Global Access Programs.
The Canadian publication is the second in a series of manuscripts that will help the rare disease community. The first publication, released in 2014, focused on accessing unlicensed medicines in the U.S.
Through its Global Access Programs (GAP), Caligor Rx is helping to provide access to investigational medicines for patients with serious or life-threatening diseases in situations where no comparable treatment option exists in the patient’s own country.
“Of the nearly 7,000 identified rare diseases, fewer than 400 have FDA-approved drug treatments, so it’s critically important to support the Global Genes mission to help physicians, patients, care givers and advocates become activists in finding innovative treatment options for these rare conditions,” Frascello said. “Our Global Access Programs provide controlled, compliant and ethical access to unlicensed medicines for patients with rare diseases, while giving pharmaceutical companies real-world data that can support further clinical development and, ultimately, commercialization.”
About Global Genes
Global Genes™ is a leading rare disease patient advocacy organization. The group’s mission is to eliminate the challenges of rare disease by providing patients with educational tools, building awareness, providing critical connections to people and resources, and through investment in technologies that will positively impact affected patients and families. Recognized worldwide by the Blue Denim Genes Ribbon™, Global Genes unites experts, advocates and patients of all ages to stand together in hope for treatments and cures for the estimated 7,000 rare and genetic diseases that impact approximately 35 million Americans and over 350 million people worldwide. For more information about Global Genes, please visit http://globalgenes.org/
Global Genes RARE Toolkits™
RARE Toolkits provide individuals with actionable information on a variety of topics related to living with and advocating for rare disease patients. RARE Toolkits are created in collaboration with key rare disease stakeholders with a vast array of subject matter expertise who believe in the importance of sharing these best practices. These important resources are made available online, in PDF format and in print. Interested parties should contact Barbara Lavery, VP Strategic Alliances, Global Genes[email protected]
About Caligor Rx
Caligor Rx strives to be the premier provider of pharmaceutical services that enable our clients to improve patients’ lives through effective, cost-efficient clinical trials and Global Access Programs. Regulatory knowledge, strong expertise in managing unlicensed medicines and a commitment to the highest ethical standards provide the foundation for everything we do. The consistent strategic value we deliver as a supply chain partner gives our clients the freedom to focus on the essence of life sciences – delivering quality outcomes. Certified by the Women’s Business Enterprise National Council as a Woman-Owned Business, Caligor Rx is licensed to distribute approved and unlicensed medicines in the continental United States and throughout Europe. Information about the Company’s services is available at www.caligorrx.com.